Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort

Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet evidence on their utilization, treatment trajectories, and effectiveness in routine clinical practice remains limited. We characterized real-world ICI use and outcomes across cancer types using the multicenter FAIR-ICI cohort and explored differences between real-world and pivotal trial outcomes. Methods: We conducted a retrospective cohort study of adults receiving ICIs across four Belgian hospitals. Structured and unstructured electronic health record data were harmonized using the Observational Medical Ou

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.